Proteomic Exploration of Paraoxonase 1 Function in Health and Disease

Int J Mol Sci. 2023 Apr 24;24(9):7764. doi: 10.3390/ijms24097764.

Abstract

High-density lipoprotein (HDL) exhibits cardio- and neuro-protective properties, which are thought to be promoted by paraoxonase 1 (PON1), a hydrolytic enzyme associated with an HDL subfraction also enriched with an anticoagulant protein (PROS1) and amyloid beta-transport protein clusterin (CLU, APOJ). Reduced levels of PON1 activity, characterized biochemically by elevated levels of homocysteine (Hcy)-thiolactone, oxidized lipids, and proteins modified by these metabolites in humans and mice, are associated with pathological abnormalities affecting the cardiovascular system (atherothrombosis) and the central nervous system (cognitive impairment, Alzheimer's disease). The molecular bases of these abnormalities have been largely unknown. Proteomic and metabolic studies over the past decade have significantly contributed to our understanding of PON1 function and the mechanisms by which PON1 deficiency can lead to disease. Recent studies discussed in this review highlight the involvement of dysregulated proteostasis in the pro-oxidative, pro-atherothrombotic, and pro-amyloidogenic phenotypes associated with low PON1 activity.

Keywords: Alzheimer’s disease; cardiovascular disease; homocysteine; oxidative stress; paraoxonase 1; proteostasis.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides
  • Animals
  • Aryldialkylphosphatase* / metabolism
  • Humans
  • Lipoproteins, HDL / metabolism
  • Mice
  • Proteomics

Substances

  • Aryldialkylphosphatase
  • Amyloid beta-Peptides
  • Lipoproteins, HDL
  • PON1 protein, human